| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| GTO ID | GTC0856 |
| Trial ID | ChiCTR2000032124 |
| Disease | B-Cell Leukemia and Lymhpoma | Multiple Myeloma | Ovarian Cancer |
| Altered gene | CD19|GMCSF|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Chimeric antigen receptor engineered T cells for treating malignant cancers |
| Year | 2020 |
| Country | China |
| Company sponsor | The Second Xiangya Hospital of Central South University |
| Cohort 1 | |||||||
|
|||||||